Iterum Therapeutics to Present Clinical Data on Antibiotic Sulopenem at ID Week 2018

DUBLIN, Ireland and CHICAGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today announced that clinical data on sulopenem, its novel oral and IV penem antibiotic, will be presented in poster sessions at IDWeek 2018, being held October 3-7 in San Francisco.

Details on the poster presentations are as follows:

Title: A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem

Poster Abstract Session: PK/PD Studies

Poster number: 1393

Date / Time: Friday, October 5, 2018, 12:30 – 1:45 p.m. PDT

Location: S Poster Hall

Presenter: Michael Dunne, M.D., Iterum Therapeutics

Title: Sulopenem Activity against Enterobacteriaceae Isolates from Patients with Urinary Tract Infection or Intra-Abdominal Infection

Poster Abstract Session: Novel Agents

Poster number: 1363

Date / Time: Friday, October 5, 2018, 12:30 – 1:45 p.m. PDT

Location: S Poster Hall

Presenter: Sailaja Puttagunta, M.D., Iterum Therapeutics

Title: The Prevalence of Enterobacteriaceae (ENT) Resistant to all Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outcomes

Poster Abstract Session: Urinary Tract Infection

Poster number: 1527

Date / Time: Friday, October 5, 2018, 12:30 – 1:45 p.m. PDT

Location: S Poster Hall

Presenter: Michael Dunne, M.D., Iterum Therapeutics

These posters will be available on the Iterum website following the IDWeek meeting. https://www.iterumtx.com/

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing sulopenem, a novel oral and IV penem anti-infective compound, in Phase 3 clinical development in uncomplicated urinary tract infection (uUTI), complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI). Sulopenem is the first oral and IV penem to demonstrate potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria that are resistant to other antibiotics in the hospital and community setting. Iterum has received QIDP designations for oral and IV sulopenem for the treatment of uUTI, cUTI and cIAI. For more information, please visit http://www.iterumtx.com.

Forward-looking Statements

This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding the development, therapeutic and market potential of sulopenem, and the timing, progress and results of clinical trials, and the expected timing of NDA filings. In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum Therapeutics’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum Therapeutics’ control, including the uncertainties inherent in the initiation and conduct of clinical trials, clinical trial patient enrolment, availability and timing of data from clinical trials, changes in regulatory requirements or decisions of regulatory authorities, commercialization plans and timelines, if approved, the actions of third-party clinical research organizations, suppliers and manufacturers and other factors discussed under the caption “Risk Factors” in the final prospectus for Iterum Therapeutics’ initial public offering, which was filed with the Securities and Exchange Commission (the “SEC”) on May 25, 2018, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum Therapeutics’ beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum Therapeutics assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Contact:

Contact:

Jeff Schaffnit

Chief Commercial Officer

312-778-6076

IR@iterumtx.com

Media Contact:

Tony Plohoros

6 Degrees

(908) 940-0135

tplohoros@6degreespr.com

This message was distributed by GlobeNewswire.

2321 Rosecrans Ave. Ste 2200, El Segundo, CA, 90245, USA. +1-800-307-6627. www.globenewswire.com

On behalf of Iterum Therapeutics plc Block 2, Floor 3 Harcourt Centre, Harcourt Street, Dublin 2, IE

This message was sent to rob@pivotalbiovp.com.

If you wish to no longer receive these messages you can unsubscribe.

Image removed by sender.

info info